Invest now

Wockhardt share price

High risk
  • 47%Low risk
  • 47%Moderate risk
  • 47%Balanced risk
  • 47%High risk
  • 47%Extreme risk
  • ₹2,056.35(1.06%)
    November 12, 2026 15:52:59 PM IST
    • NSE
    • BSE
  • Vol : 388.16 K (NSE + BSE)
    Last 20 day avg : 678.69 K
Wockhardt is trading 1.06% upper at Rs 2,056.35 as compared to its last closing price. Wockhardt has been trading in the price range of 2,064.00 & 2,029.85. Wockhardt has given 42.03% in this year & 3.23% in the last 5 days. Wockhardt has TTM P/E ratio 83.81 as compared to the sector P/E of 39.52.The company posted a net profit of 79.00 Crores in its last quarter.Listed peers of Wockhardt include Sun Pharmaceutical Industries (-0.49%), Divi's Laboratories (1.19%), Torrent Pharmaceuticals (-0.92%).The Mutual Fund holding in Wockhardt was at 5.99% in 30 Sep 2026. The MF holding has decreased from the last quarter. The FII holding in Wockhardt was at 7.02% in 30 Sep 2026. The FII holding has decreased from the last quarter.
  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Loading...
Key Metrics

Updated on 13 Nov 2026, 08:13 AM IST

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    1.31
    High volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.45
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.00
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    6.69
    Lower than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
2,029.85
Highest
2,064.00
52 week range
Lowest
1,086.80
Highest
2,420.00
Wockhardt Peers
Return Comparison
Peers Comparison
Names
Price%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Sun Pharmaceutical Industries
1,886.80-0.494,52,695.8538.405.550.830.47
Divi's Laboratories
11,450.001.193,03,961.5273.3211.480.410.03
Torrent Pharmaceuticals
4,718.95-0.921,79,487.2772.7319.220.80141.16
Cipla
1,410.00-0.491,13,912.2227.573.330.921.11
Zydus Lifesciences
1,205.501.291,20,249.0921.194.240.0914.22
Mutual Fund Ownership
View all
Samco Active Momentum Fund Regular Growth
NA
  • Amount Invested (Cr.) 46.16
  • % of AUM 5.38
ITI Focused Equity Fund Regular Growth
NA
  • Amount Invested (Cr.) 21.79
  • % of AUM 4.27
Tata India Pharma & Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 40.28
  • % of AUM 3.27
HDFC Pharma and Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 50.31
  • % of AUM 2.95
Mirae Asset Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 75.70
  • % of AUM 2.81
Wockhardt Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-11-02Quarterly Results
2026-08-10Quarterly Results
2026-05-04Audited Results & Others
2026-02-10Quarterly Results
2025-11-03Quarterly Results
About the company Wockhardt
  • IndustryBiotechnology & Drugs
  • ISININE049B01025
  • BSE Code532300
  • NSE CodeWOCKPHARMA
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
  • Management Info
  • Habil Fakhruddin KhorakiwalaExecutive Chairman of the Board, Founder
  • Deepak MadnaniChief Financial Officer
  • Rashmi MamturaCompliance Officer, Company Secretary
  • Murtaza Habil KhorakiwalaManaging Director, Executive Director
  • Huzaifa Habil KhorakiwalaExecutive Director
Wockhardt Share Price FAQs

Wockhardt is trading at 2056.35 as on Thu Nov 12 2026 10:22:59. This is 1.06% upper as compared to its previous closing price of 2034.70.

The market capitalization of Wockhardt is 33392.12 Cr as on Thu Nov 12 2026 10:22:59.

The 52 wk high for Wockhardt is 2420.00 whereas the 52 wk low is 1086.80

Wockhardt can be analyzed on the following key metrics -

  • TTM P/E: 83.81
  • Sector P/E: 39.52
  • Dividend Yield: 0.00%
  • D/E ratio: 0.43

Wockhardt reported a net profit of 213.00 Cr in 2026.

The Mutual Fund Shareholding was 5.99% at the end of 30 Sep 2026.